All episodes

Episode 59: Epilepsy and Travel

Moderator: Barbara Tettenborn (St. Gallen, Switzerland)
Guests: Simona Balestrini (Florence, Italy), Marian Galovic (Zurich, Switzerland)

In the first episode of August, Barbara Tettenborn discusses epilepsy and traveling with experts Simona Balestrini and Marian Galovich. They address various topics related to epilepsy and travel, including recommendations for people with epilepsy when flying, adjusting medication schedules for time zone changes, managing temperature-related challenges, dealing with infections, vaccinations, and considerations for physical activities like swimming and scuba diving.

Episode 58: EAN 2023 Review
Moderator: Barbara Tettenborn (Bern, Switzerland)
Guest: Thomas Berger (Vienna, Austria)
In this special episode, EAN moderator Prof. Barbara Tettenborn sits down with fellow moderator and chair of the scientific committee, Prof. Thomas Berger, to review highlights and details about the EAN congress 2023.

Moderator: Barbara Tettenborn (Bern, Switzerland)

Guest: Miguel Silva Miranda (Cascais, Portugal)

In this episode, Prof. Tettenborn and Dr. Silva discuss the connection between neurology and climate change. They explore the growing body of evidence linking climate change to neurological diseases, such as stroke, headache, multiple sclerosis, epilepsy, and neuroinfectious diseases. They also highlight the importance of sustainability in promoting brain health and discuss the European Academy of Neurology's commitment to implementing sustainable actions in their initiatives and events.

Moderator: Thomas Berger (Vienna, Austria)

Guest: Harris Eyre (Houston, USA)

Prof. Thomas Berger is joined by special guest, Dr. Harris Eyre to discuss brain capital, and how brain health is becoming increasingly important for modern society.

Moderator: Rolf Fronczek (Leiden, The Netherlands)

Guest: David Schreier (Bern, Switzerland), Matthieu Perrenoud (Lausanne, Switzerland)

The EAN mentorship programme is dedicated to helping neurologists in Europe to successfully manage these challenges by facilitating the transition of knowledge and experience across generations of neurologists. Moderator Dr. Rolf Fronczek sits down with Dr. David Schreier and Dr. Matthieu Perrenoud to discuss this programme, as well as their experiences on the Mentorship Task Force.

Moderator: Rolf Fronczek (Leiden, The Netherlands)

Guest: Katina Aleksovska (Skopje, North Macedonia)

Dr. Katina Aleksovska joins Dr. Rolf Fronczek in an enlightening discussion about the fundamental aspects of guideline creation and Dr. Aleksovska’s personal experience with the Guideline Production Group (GPG). Gain practical insights into the ins and outs of the process and discover how guideline production unfolds within EAN.

Moderator: Dag Aarsland (London, United Kingdom)

Guest: Laura Bonanni (Chieti, Italy)

In this episode, specialist Moderator Dag Aarsland is joined by Prof. Laura Bonanni to talk about the understanding of the prodromal in dementia with Lewybodies (DLB), the role of different diagnostic methods and management of prodromal DLB.

Moderator: Elka Stefanova (Belgrade, Serbia)

Guest: Magda Tsolaki (Thessaloniki, Greece)

Elka Stefanova is joined by Magda Tsolaki to discuss the basics of diagnosis and treatment of neurodegenerative dementia.

Moderator: Kristian Steen Frederiksen (Copenhagen, Denmark)

Guest: Svetlana Tomic (Osijek, Croatia)

In this second episode, Moderator Kristian Steen Frederiksen is joined by Prof. Svetlana Tomic to talk about gut microbiota in context with neurodegenerative diseases.

Moderator: Kristian Steen Frederiksen (Copenhagen, Denmark)

Guest: Lutz Fröhlich (Mannheim, Germany)

The field of dementia and specifically the treatment of Alzheimer´s disease is at the brink of a possible new era in which disease-modifying therapy will become available in the form of anti-bodies directed against beta-amyloid.

Prof. Kristian Steen Frederiksen and Prof. Lutz Fröhlich kick off the June episodes on Dementia and Cognitive Disorderswith discussions on the background and development of anti-bodies directed against beta-amyloid development, status with regards to clinical trials in AD of anti-amyloid anti-body therapy, and challenges and opportunities in clinical practice if anti-amyloid anti-body therapy will...